RECRUITING

Lutein, Zeaxathin, and Fish Oil Supplementation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to learn the impact of lutein, zeaxanthin, and fish oil (LZF) supplementation in healthy adults. The main question it aims to answer is: Will supplementation with LZF improve macular pigment optical density (MPOD), cognitive performance and bone mass compared to controls after six months? Subjects with an MPOD \<.43 will significantly improve MPOD after 6-months of LZF supplementation. Consuming a LZFO supplement for 6-months will improve visual cognitive performance. Consuming a LZFO supplement for 6-months will improve bone density. Participants will be asked to take either a LZF supplement or placebo daily for 6 months.

Official Title

The Role of Lutein, Zeaxanthin, and Fish Oil on Cognitive Function and Bone Health in Healthy Adults

Quick Facts

Study Start:2024-02-07
Study Completion:2025-05-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06489873

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 45 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * \<.43 MPOD, a self-reported best-corrected vision of 20/40 or better in each eye, a BMI range of 18.5-30, and meets the inclusion criteria on the preliminary participant questionnaire.
  1. * allergic to lutein, zeaxanthin, or fish oil, taking supplements with \>6 mg lutein and/or \>2 mg zeaxanthin for more than two months before study starts, MPOD between \>.43, self-reported condition of vertigo, diabetic retinopathy, retinitis pigmentosa, optic neuropathy, retinal vascular occlusions, strabismus, autoimmune disorders related to visual health, currently pregnant or trying to become pregnant, history of concussion, vegan (due to gelatin in the placebo), and/or taking neuroactive medications, such as Ritalin, Adderall, antidepressants, etc.

Contacts and Locations

Study Contact

Karen M Beathard, PhD
CONTACT
979-220-2281
karen-beathard@tamu.edu
Steven E Riechman, PhD
CONTACT
979-862-3213
sriechman@tamu.edu

Principal Investigator

Karen M Beathard, PhD
PRINCIPAL_INVESTIGATOR
Texas A&M University

Study Locations (Sites)

Gilchrist Building
College Station, Texas, 77843
United States

Collaborators and Investigators

Sponsor: Texas A&M University

  • Karen M Beathard, PhD, PRINCIPAL_INVESTIGATOR, Texas A&M University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-02-07
Study Completion Date2025-05-01

Study Record Updates

Study Start Date2024-02-07
Study Completion Date2025-05-01

Terms related to this study

Keywords Provided by Researchers

  • Lutein
  • Zeaxanthin
  • Fish Oil
  • Supplement
  • Macular Pigment
  • Macular Pigment Optical Density
  • Cognition
  • Age-related Macular Degeneration
  • Cognitive Performance

Additional Relevant MeSH Terms

  • Cognitive Performance
  • Age-Related Macular Degeneration
  • Bone Loss